<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomark Res</journal-id><journal-id journal-id-type="iso-abbrev">Biomark Res</journal-id><journal-title-group><journal-title>Biomarker Research</journal-title></journal-title-group><issn pub-type="epub">2050-7771</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40188144</article-id><article-id pub-id-type="pmc">PMC11972456</article-id>
<article-id pub-id-type="publisher-id">768</article-id><article-id pub-id-type="doi">10.1186/s40364-025-00768-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Comprehensive plasma metabolomics profiling develops diagnostic biomarkers of obstructive hypertrophic cardiomyopathy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cui</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Yifan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hua</surname><given-names>Xiumeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mo</surname><given-names>Han</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hongmei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Siyuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yiqi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Qian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Song</surname><given-names>Jiangping</given-names></name><address><email>fwsongjiangping@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, </institution><institution>Chinese Academy of Medical Sciences and Peking Union Medical College, </institution></institution-wrap>Beijing, 100037 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>Beijing Key Laboratory of Preclinical Research and Evaluation for Cardiovascular Implant Materials, Animal Experimental Centre, National Centre for Cardiovascular Disease, </institution><institution>Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, </institution></institution-wrap>167A Beilishi Road, Xi Cheng District, Beijing, 100037 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, </institution><institution>Chinese Academy of Medical Sciences and Peking Union Medical College, </institution></institution-wrap>Beijing, 100037 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00t7sjs72</institution-id><institution>Shenzhen Key Laboratory of Cardiovascular Disease, </institution><institution>Fuwai Hospital Chinese Academy of Medical Sciences, </institution></institution-wrap>Shenzhen, 518057 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>Department of Cardiac Surgery, Fuwai Yunnan Hospital, </institution><institution>Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, </institution></institution-wrap>Kunming, China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>55</elocation-id><history><date date-type="received"><day>25</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Hypertrophic cardiomyopathy (HCM) is the common cause of sudden cardiac death in young people and is characterized by cardiac hypertrophy. Non-HCM caused left ventricular hypertrophy (LVH) is more common in the population, especially in people with hypertension, obesity, and diabetes. In order to identify high-risk populations, a screening technique that can rapidly differentiate between HCM and LVH patients should be developed. Plasma metabolomics may help develop useful biomarkers for the disease diagnosis. We performed a comprehensive plasma metabolomic analysis on a total of 720 individuals, included 441 HCM patients, 160 LVH patients, and 119 normal controls (NC) (derivation cohort&#x02009;=&#x02009;368, validation cohort&#x02009;=&#x02009;352). Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to construct discriminant models based on metabolomics, and the result showed significant changes in plasma metabolic profiling among the HCM, LVH, and NC. The prospective diagnostic biomarkers for HCM patients have been examined using variable importance in projection, fold change, and FDR. Acylcarnitines efficiently distinguished HCM and LVH patients, with a C14:0-carnitine AUC of 0.937 shown by the reiver operator characteristic (ROC) curve analysis. The biomarkers for the diagnosis of HCM patients was verified in another independent validation cohort. This study is the largest plasma metabolomics analysis of Chinese Han patients with HCM, finding biomarkers that can be used to distinguish between HCM from LVH patients. These results highlight the great potential value of plasma metabolic profiling analysis on HCM diagnoses.</p><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1186/s40364-025-00768-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hypertrophic cardiomyopathy</kwd><kwd>Left ventricular hypertrophy</kwd><kwd>Biomarker</kwd><kwd>Metabolomics</kwd><kwd>Diagnosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>the National Natural Science Foundation of China for Distinguished Young Scholars</institution></funding-source><award-id>82125004</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Yumed Inc. and BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>To the editor</title><p id="Par2">Hypertrophic cardiomyopathy is characterized clinically by left ventricular hypertrophy and pathologically by cardiomyocyte enlargement and disarray, interstitial fibrosis, and inflammatory cell infiltration. (<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR2">2</xref>) Patients with HCM may develop some complications and even sudden cardiac death, that may exert tremendous financial, social, and medical burdens on the healthcare system. (<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>) Screening of HCM depend on imaging modalities and genetic testing [<xref ref-type="bibr" rid="CR5">5</xref>]. However, the expensive medical costs, time commitment, and reliance on expert supervision severely limit the widespread screening of HCM. Here, we perform metabolomic analysis with LC-MS on a total of 720 plasma samples. The derivation cohort was including 207 HCM patients, 104 LVH patients, and 57 NC, whereas validation cohort was including 234 HCM patients, 56 LVH patients, and 62 NC (Supplementary materials Tables <xref rid="MOESM1" ref-type="media">1</xref>,<xref rid="MOESM1" ref-type="media">2</xref>; Supplementary materials Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>A, B). A total of 406 metabolites were successfully identified (Supplementary materials Table <xref rid="MOESM1" ref-type="media">3</xref>).</p><p id="Par3">The plasma metabolome revealed substantial differences across the HCM, LVH, and NC. An OPLS-DA revealed distinct metabolic differences between HCM vs. LVH (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A), HCM vs. NC (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B), and LVH vs. NC (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C). All of the predicted variance, predictive ability, and CV-ANOVA <italic>P</italic>&#x02009;values suggested that the OPLS-DA model was robust and trustworthy (Supplementary materials Table <xref rid="MOESM1" ref-type="media">4</xref>). The permutation test demonstrated that the OPLS-DA models had not been overfitted (Supplementary materials Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>C-E). We identified 83 differential metabolites in HCM vs. LVH, 103 in HCM vs. NC, and 79 in LVH vs. NC (Mann-Whitney U test, FDR&#x02009;&#x0003c;&#x02009;0.05 and|FC| &#x0003e; 2) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D&#x02013;F). The KEGG pathway analysis revealed that the differential metabolites in HCM vs. LVH, HCM vs. NC, and LVH vs. NC were enriched in arginine and proline metabolism, cysteine and methionine metabolism, and histidine metabolism, respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>G-I). The result of unsupervised hierarchical clustering showed that the metabolic profiling of HCM was considerably different from the other two groups (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>J).</p><p id="Par4">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Plasma metabolic profiling of HCM patients, LVH patients, and NC. The OPLS-DA score plots of plasma metabolomes in HCM, LVH, and NC were shown as (<bold>A</bold>) HCM vs. LVH, (<bold>B</bold>) HCM vs. NC, and (<bold>C</bold>) LVH vs. NC in the derivation cohort. There were significant differences in the level of plasma metabolite between the two groups: (<bold>D</bold>) HCM vs. LVH, (<bold>E</bold>) HCM vs. NC, and (<bold>F</bold>) LVH vs. NC in the derivation cohort. Using Mann-Whitney U test, <italic>P</italic>-values adjusted by FDR, FDR&#x02009;&#x0003c;&#x02009;0.05, are represented in the volcano plot, with red representing (fold change&#x02009;&#x0003e;&#x02009;2) and blue representing (fold change&#x02009;&#x0003c;&#x02009;0.5). KEGG pathways were enriched with significantly different metabolites between the two groups: (<bold>G</bold>) HCM vs. LVH, (<bold>H</bold>) HCM vs. NC, and (<bold>I</bold>) LVH vs. NC in the derivation cohort. All pathways are represented by bubbles. Each pathway was represented by bubbles. Bubble&#x02019;s color and size were based on <italic>P</italic>-value and RichFactor. (<bold>J</bold>) A hierarchical clustering heatmap revealed significantly different expression metabolites across HCM, LVH, and NC in the derivation cohort. HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; NC, normal controls; OPLS-DA, orthogonal partial least squares discriminant analysis; FDR, false discovery rates; KEGG, kyoto encyclopedia of genes and genomes</p></caption><graphic xlink:href="40364_2025_768_Fig1_HTML" id="d33e362"/></fig>
</p><p id="Par5">The three groups were compared in pairs (HCM vs. LVH, HCM vs. NC, and LVH vs. NC) to screen the biomarkers through the several steps (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, B). The top five biomarkers which showed an excellently predictive effect with the AUC up to 0.94, 0.99, and 0.97 in the comparation of HCM vs. LVH, HCM vs. NC, and LVH vs. NC, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C-E). Long-chain acylcarnitines demonstrated exceptionally strong and consistent diagnostic performance in distinguishing between HCM and LVH, and C14:0-carnitine exhibited the larger AUC (0.94; 95% CI, 0.91&#x02013;0.96) than the others (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C, F). We further investigated the gain effect of C14:0-carnitine on clinical parameters. The AUC of NT-proBNP alone was 0.71, while the AUC increased to 0.95 when combined with C14:0 carnitine (Supplementary materials Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>). Compared with NC, plasma level of ATP, ADP, and AMP were significantly lower in HCM patients. This suggests that HCM is also characterized by abnormal energy metabolism, even if systolic dysfunction is not present. The metabolic differences between LVH and NC are predominantly focused on amino acid metabolism [<xref ref-type="bibr" rid="CR6">6</xref>]. The metabolomic analysis was carried out independently in a validation cohort to confirm the predictive efficiency of the biomarkers. In the comparison of HCM vs. LVH, HCM vs. NC, and LVH vs. NC, the AUC values were 0.83&#x02013;1.0, 0.89&#x02013;0.99, and 0.6&#x02013;1.0 (Supplementary materials Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>). It was demonstrated that the application, reproducibility, and validity of predict performance of these biomarkers.</p><p id="Par6">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Prediction model based on plasma metabolome for HCM diagnosis in the derivation cohort. (<bold>A</bold>) Potential diagnostic biomarker screening procedure. (<bold>B</bold>) Venn diagram showing differential metabolites comparison between HCM, LVH, and NC groups in the derivation cohort. ROC curve analysis was performed to evaluate diagnostic effect between two groups in derivation cohort, (<bold>C</bold>) HCM vs. LVH, (<bold>D</bold>) HCM vs. NC, (<bold>E</bold>) LVH vs. NC in the derivation cohort. (<bold>F</bold>) Boxplot demonstrating the relative expression levels of the typical biomarkers for HCM, LVH, and NC in the derivation cohort. HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy; NC, normal controls; ROC, receiver operator characteristic</p></caption><graphic xlink:href="40364_2025_768_Fig2_HTML" id="d33e413"/></fig>
</p><p id="Par7">Metabolomics has been widely used in the research of cardiomyopathy, and it has the potential to provide considerable predictive value independent of traditional risk factors. (<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>) The biomarkers identified in this study, such as acylcarnitines, were also shown to be beneficial for DCM diagnosis [<xref ref-type="bibr" rid="CR9">9</xref>]. Although of obvious importance, data on the application of metabolomics in HCM is scarce. The present study, with a larger sample size, used LVH patients as controls to fill this gap in metabolomics data in this field. In our previous studies, we have also successfully applied metabolomics to cardiomyopathies such as dilated cardiomyopathy, diabetic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. These studies may provide important insights into the pathophysiology of cardiomyopathy. Nevertheless, our study has potential limitations, particularly with patients who were candidates for septal myectomy, it may not generalize to patients with mild clinical manifestations of HCM. Future use of prospective cohorts is required to validate the findings of this study.</p></sec><sec id="Sec2" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40364_2025_768_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Hao Cui, Yifan Wang and Xiumeng Hua contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to express our sincere gratitude to the patients who enrolled in this cohort.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>H.C., Y.W., X.H., J.H., H.M., S.L., and H.W. collected the samples. H.C., and J.H. performed the LC&#x02013;MS analysis. H.C., Y.W., S.H., and Y.Z. performed the data analyses. H.C., X.H., X.C., Q.Z., H.J., and Y.C. performed the statistical analysis. H.C., Y.W., and J.S. generated the figures and wrote the original manuscript. J.S. supervised the study and finalized the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by grants from the National Natural Science Foundation of China for Distinguished Young Scholars (Grant No. 82125004).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data underlying this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par8">This study was approved by the Ethics Committee of Fuwai Hospital and carried out in accordance with the Helsinki Declaration of 1964. The individuals who took part in this study provided written informed consent.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par9">All authors have approved this manuscript and affirm that it has not been previously published nor is it under consideration by another journal. Written informed consent for publication was obtained from all participants.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par10">The authors disclose no competing financial conflict of interest.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>HCM</term><def><p id="Par11">Hypertrophic cardiomyopathy</p></def></def-item><def-item><term>LVH</term><def><p id="Par12">Non-HCM caused left ventricular hypertrophy</p></def></def-item><def-item><term>NC</term><def><p id="Par13">Normal control</p></def></def-item><def-item><term>LC-MS</term><def><p id="Par14">Liquid chromatography-mass spectrometry</p></def></def-item><def-item><term>AUC</term><def><p id="Par15">Area under curve</p></def></def-item><def-item><term>OPLS-DA</term><def><p id="Par16">Orthogonal partial least squares discriminant analysis</p></def></def-item><def-item><term>FC</term><def><p id="Par17">Fold change</p></def></def-item><def-item><term>FDR</term><def><p id="Par18">False discovery rates</p></def></def-item><def-item><term>KEGG</term><def><p id="Par19">Kyoto encyclopedia of genes and genomes</p></def></def-item><def-item><term>ATP</term><def><p id="Par20">Adenosine triphosphate</p></def></def-item><def-item><term>ADP</term><def><p id="Par21">Adenosine diphosphate</p></def></def-item><def-item><term>AMP</term><def><p id="Par22">Adenosine monophosphate</p></def></def-item><def-item><term>DCM</term><def><p id="Par23">Dilated cardiomyopathy</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Marian</surname><given-names>AJ</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Hypertrophic cardiomyopathy</article-title><source>Circul Res</source><year>2017</year><volume>121</volume><issue>7</issue><fpage>749</fpage><lpage>70</lpage></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Marian AJ, Braunwald E. Hypertrophic cardiomyopathy. Circul Res. 2017;121(7):749&#x02013;70.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Lentz Carvalho</surname><given-names>J</given-names></name><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Geske</surname><given-names>JB</given-names></name><name><surname>Dearani</surname><given-names>JA</given-names></name><name><surname>Lahr</surname><given-names>BD</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Bos</surname><given-names>JM</given-names></name><name><surname>Ackerman</surname><given-names>MJ</given-names></name><name><surname>Ommen</surname><given-names>SR</given-names></name><name><surname>Maleszewski</surname><given-names>JJ</given-names></name></person-group><article-title>Myocardial histopathology in patients with obstructive hypertrophic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>77</volume><issue>17</issue><fpage>2159</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">33926651</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cui H, Schaff HV, Lentz Carvalho J, Nishimura RA, Geske JB, Dearani JA, Lahr BD, Lee AT, Bos JM, Ackerman MJ, Ommen SR, Maleszewski JJ. Myocardial histopathology in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;77(17):2159&#x02013;70.<pub-id pub-id-type="pmid">33926651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>MJ</given-names></name><name><surname>Sonnenberg</surname><given-names>B</given-names></name><name><surname>Woo</surname><given-names>A</given-names></name><name><surname>Rakowski</surname><given-names>P</given-names></name><name><surname>Parker</surname><given-names>TG</given-names></name><name><surname>Wigle</surname><given-names>ED</given-names></name><name><surname>Rakowski</surname><given-names>H</given-names></name></person-group><article-title>Long-term outcome in patients with apical hypertrophic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>39</volume><issue>4</issue><fpage>638</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">11849863</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED, Rakowski H. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(4):638&#x02013;45.<pub-id pub-id-type="pmid">11849863</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Lumish</surname><given-names>HS</given-names></name><name><surname>Sherrid</surname><given-names>MV</given-names></name><name><surname>Janssen</surname><given-names>PML</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Castillero</surname><given-names>E</given-names></name><name><surname>Adlestein</surname><given-names>E</given-names></name><name><surname>Swistel</surname><given-names>DG</given-names></name><name><surname>Topkara</surname><given-names>VK</given-names></name><name><surname>Maurer</surname><given-names>MS</given-names></name><name><surname>Reilly</surname><given-names>MP</given-names></name><name><surname>Shimada</surname><given-names>YJ</given-names></name></person-group><article-title>Comprehensive proteomic profiling of human myocardium reveals signaling pathways dysregulated in hypertrophic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2024</year><volume>84</volume><issue>20</issue><fpage>1999</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">39365226</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lumish HS, Sherrid MV, Janssen PML, Ferrari G, Hasegawa K, Castillero E, Adlestein E, Swistel DG, Topkara VK, Maurer MS, Reilly MP, Shimada YJ. Comprehensive proteomic profiling of human myocardium reveals signaling pathways dysregulated in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2024;84(20):1999&#x02013;2011.<pub-id pub-id-type="pmid">39365226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>PM</given-names></name><name><surname>Anastasakis</surname><given-names>A</given-names></name><name><surname>Borger</surname><given-names>MA</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name><name><surname>Cecchi</surname><given-names>F</given-names></name><name><surname>Charron</surname><given-names>P</given-names></name><name><surname>Hagege</surname><given-names>AA</given-names></name><name><surname>Lafont</surname><given-names>A</given-names></name><name><surname>Limongelli</surname><given-names>G</given-names></name><name><surname>Mahrholdt</surname><given-names>H</given-names></name><name><surname>McKenna</surname><given-names>WJ</given-names></name><name><surname>Mogensen</surname><given-names>J</given-names></name><name><surname>Nihoyannopoulos</surname><given-names>P</given-names></name><name><surname>Nistri</surname><given-names>S</given-names></name><name><surname>Pieper</surname><given-names>PG</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><name><surname>Rapezzi</surname><given-names>C</given-names></name><name><surname>Rutten</surname><given-names>FH</given-names></name><name><surname>Tillmanns</surname><given-names>C</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name></person-group><article-title>2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC)</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><issue>39</issue><fpage>2733</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">25173338</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC). Eur Heart J. 2014;35(39):2733&#x02013;79.<pub-id pub-id-type="pmid">25173338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name></person-group><article-title>Novel biomarkers identifying hypertrophic cardiomyopathy and its obstructive variant based on targeted amino acid metabolomics</article-title><source>Chin Med J (Engl)</source><year>2022</year><volume>135</volume><issue>16</issue><fpage>1952</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">36156511</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Guo L, Wang B, Zhang F, Gao C, Hu G, Zhou M, Wang R, Zhao H, Yan W, Zhang L, Ma Z, Yang W, Guo X, Huang C, Cui Z, Sun F, Song D, Liu L, Tao L. Novel biomarkers identifying hypertrophic cardiomyopathy and its obstructive variant based on targeted amino acid metabolomics. Chin Med J (Engl). 2022;135(16):1952&#x02013;61.<pub-id pub-id-type="pmid">36156511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Virz&#x000ec;</surname><given-names>GM</given-names></name><name><surname>Clementi</surname><given-names>A</given-names></name><name><surname>Battaglia</surname><given-names>GG</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name></person-group><article-title>Multi-Omics approach: new potential key mechanisms implicated in cardiorenal syndromes</article-title><source>Cardiorenal Med</source><year>2019</year><volume>9</volume><issue>4</issue><fpage>201</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30939477</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Virz&#x000ec; GM, Clementi A, Battaglia GG, Ronco C. Multi-Omics approach: new potential key mechanisms implicated in cardiorenal syndromes. Cardiorenal Med. 2019;9(4):201&#x02013;11.<pub-id pub-id-type="pmid">30939477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Zhao B-R, Hu X-R, Wang W-D, Zhou Y. Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies. Acta Pharmacol Sin. 2025;0:1&#x02013;17.</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Ampong</surname><given-names>I</given-names></name></person-group><article-title>Metabolic and metabolomics insights into dilated cardiomyopathy</article-title><source>Ann Nutr Metab</source><year>2022</year><volume>78</volume><issue>3</issue><fpage>147</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">35472668</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ampong I. Metabolic and metabolomics insights into dilated cardiomyopathy. Ann Nutr Metab. 2022;78(3):147&#x02013;55.<pub-id pub-id-type="pmid">35472668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Changes of plasma Tris(hydroxymethyl)aminomethane and 5-Guanidino-3-methyl-2-oxopentanoic acid as biomarkers of heart remodeling after left ventricular assist device support</article-title><source>Metabolites</source><year>2022</year><volume>12</volume><issue>11</issue><fpage>1068</fpage><pub-id pub-id-type="pmid">36355151</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Xu M, Cui H, Chen X, Hua X, Song J, Hu S. Changes of plasma Tris(hydroxymethyl)aminomethane and 5-Guanidino-3-methyl-2-oxopentanoic acid as biomarkers of heart remodeling after left ventricular assist device support. Metabolites. 2022;12(11):1068.<pub-id pub-id-type="pmid">36355151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Suppression of RCAN1 alleviated lipid accumulation and mitochondrial fission in diabetic cardiomyopathy</article-title><source>Metab Clin Exp</source><year>2024</year><volume>158</volume><fpage>155977</fpage><pub-id pub-id-type="pmid">39053690</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Shu S, Cui H, Liu Z, Zhang H, Yang Y, Chen X, Zeng Z, Du L, Fu M, Yang Z, Wang P, Wang C, Gao H, Yang Q, Lin X, Yang T, Chen Z, Wu S, Wang X, Zhao R, Hu S, Song J. Suppression of RCAN1 alleviated lipid accumulation and mitochondrial fission in diabetic cardiomyopathy. Metab Clin Exp. 2024;158:155977.<pub-id pub-id-type="pmid">39053690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J-P</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>N-N</given-names></name><name><surname>Tirasawasdichai</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>Z-L</given-names></name><name><surname>Hua</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>Y-R</given-names></name><name><surname>Tang</surname><given-names>H-R</given-names></name><name><surname>Chen</surname><given-names>H-SV</given-names></name><name><surname>Hu</surname><given-names>S-S</given-names></name></person-group><article-title>Elevated plasma &#x003b2;-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy</article-title><source>Sci Transl Med</source><year>2020</year><volume>12</volume><issue>530</issue><fpage>eaay8329</fpage><pub-id pub-id-type="pmid">32051229</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Song J-P, Chen L, Chen X, Ren J, Zhang N-N, Tirasawasdichai T, Hu Z-L, Hua W, Hu Y-R, Tang H-R, Chen H-SV, Hu S-S. Elevated plasma &#x003b2;-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy. Sci Transl Med. 2020;12(530):eaay8329.<pub-id pub-id-type="pmid">32051229</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>